Folic acid supplementation does not prevent ribavirin-induced anemia

Puerto Rico Health Sciences Journal

Volumn 22, Issue 4, 2003, Pages 359-362

  González, Henry ^a   Ríos, María E ^a   Torres, Esther A ^a   Muñoz, Humberto ^a   Arroyo, Javier ^a   Castro, Fernando J ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Anemia; Hepatitis C; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; FOLIC ACID; HAPTOGLOBIN; HEMOGLOBIN; INTERFERON; RIBAVIRIN;

ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MALE; MIDDLE AGED;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; FEMALE; FOLIC ACID; HAPTOGLOBINS; HEMOGLOBINS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 1642445662     PISSN: 07380658     EISSN: 23736011     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. WHO. Global surveillance and control of hepatitis C. Report of WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium..1 Viral Hepat 1999;6:35-47.
2. Alter MJ. Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988-1994. N Enl J Med 1999;341: 556-562.
3. Poynard T ct al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
4. Glue P. The clinical pharmacology of Ribavirin. Sem Liver Dis 1999:19:17-24.
5. Me Hutchison J, Gordon S, Schiff, ct al. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N bngl J Med 1998;339:1485-1492.
6. Poynard T, Marccllin P. Lee S, et al. Randomized trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
7. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment naive patients. Semin Liver Dis 1999; 19 SuppI 1:67-75.
8. Liu YK. Folic acid deficiency in sickle cell anemia. Scand J Hematol 1975;14:71-79.
9. Rabb LM, Grandison Y, Mason K, Hayes RJ, Serjeant B, Seijeant GR. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 1983;54:589-594.
10. Dhar M, Bellevue R, Carmel R. Pernicious anemia with neuropsychiatric dysfunction in a patients with sickle cell anemia treated with folate supplementation. N Engl J Med 2003,348:2204-2207.
11. Hoffer LJ. Folate supplementation in sickle cell anemia. N Engl J Med 2003:349:813.
12. Cosgriff TM, Hodgson LA, Canonico PG. White JD. Kastello MD, Don Ross PE. Morphological alterations in blood and bone marrow of ribavirin treated monkeys. Acta Haematol 1984;72:195-200.
13. Canonico PG. Kastello MD. Cosgriff TM, Donovan JC, Ross PE. Hematological and bone marrow effects of ribavirin in Rehus monkeys. Toxicol Appl Pharmacol 1984;74:163-172.
14. McHutchison JG et al. Retrospective analysis of adherence to treatment in interferon alfa-2b/ ribavirin trial. Hepatology 2000;32:223-A.
15. Wasserman R. Once weekly epoetin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy. Hepatology 2000; 32:368A.
16. De Franceschi L, Fattovich G, Turrini F et al. Hemolytic anemia induced by ribavirin therapy in patients with hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000A:31:997-1004.
17. Brass CA, Piken E. Do antioxidants ameliorate ribavirin related anemia in HCV patients. Gastroenterology 1999; 116:A1192-93 # L0056.